Portfolio Detail Dura Biotech

Venture Portfolio

Dura Biotech

About:
Some 17,000 people, mostly children and senior citizens, cannot have lifesaving heart valves implanted because the available options are too large. Dura Biotech’s key innovation is a thinner heart valve—specifically, a transcatheter aortic valve that is thirty-three percent smaller than anything on the market. Dura Biotech’s implant can be delivered through an artery in the leg rather than the heart, eliminating the need for open-heart surgery, a procedure that is risky for many patients and has a long recovery time.

Contact:
Eric Sirois

Website:
www.durabiotech.com

CI Representative:
Patrick O’Neill
Director, Investments

back to portfolio